Clinical Efficacy in Previously Untreated Patients REBETRON™ Combination Therapy containing REBETOL® (Ribavirin, USP) Capsules and INTRON® A (Interferon alfa-2b, recombinant) Injection Achieves 40%* sustained virologic response in previously untreated patients Sustained Loss of Detectable HCV RNA... 40% of patients (198/496) remained HCV-RNA negative† at 24 weeks posttreatment* Comparative Virologic Response Rates: REBETRON Combination Therapy vs INTRON® A Monotherapy *Combined results from two multicenter, randomized, double-blind studies evaluating 1,711 chronic hepatitis C patients who were previously untreated. Dosing regimen/duration: INTRON® A 3 MIU tiw plus either placebo or REBETOL® 1200 mg daily (1000 mg daily for patients weighing less than or equal to 165 lbs) for either 48 weeks or 24 weeks with 24 weeks of off-therapy follow-up. Results: Study 1 (n=912): Sustained virologic response in 85/228 REBETRON Combination Therapy patients vs. 27/225 INTRON A/placebo patients. Study 2 (n=799): Sustained virologic response in 113/268 REBETRON Combination Therapy patients vs. 46/266 INTRON /placebo patients. † Defined as HCV RNA levels below limits of detection using a research-based RT-PCR assay at end of treatment and during follow-up period. ...And Greater Improvements in Liver Histology 40% of biopsied patients (198/496) showed histologic improvement vs. 27% (134/491). Combined results. 6 of 11 Terms and Conditions | Privacy Policy | Important Safety Information